| Literature DB >> 33330034 |
Alexander M Knops1, Andrew South2, Ulrich Rodeck2, Ubaldo Martinez-Outschoorn3, Larry A Harshyne4, Jennifer Johnson3, Adam J Luginbuhl5, Joseph M Curry5.
Abstract
INTRODUCTION: The progression and clinical course of head and neck squamous cell carcinoma (HNSCC) relies on complex interactions between cancer and stromal cells in the tumor microenvironment (TME). Among the most abundant of these stromal cells are cancer-associated fibroblasts (CAFs). While their contribution to tumor progression is widely acknowledged, and various CAF-targeted treatments are under development, the relationship between CAF density and the clinicopathologic course of HNSCC has not been clearly defined. Here we examine the published evidence investigating the relationship of cancer-associated fibroblasts to local recurrence and indicators of prognostic significance in HNSCC.Entities:
Keywords: CAF; alpha-smooth muscle actin; cancer-associated fibroblasts; head and neck squamous cell carcinoma; myofibroblast; prognosis; tumor microenvironment
Year: 2020 PMID: 33330034 PMCID: PMC7729160 DOI: 10.3389/fonc.2020.565306
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flowchart of systematic review.
Characteristics of studies evaluating CAF density and clinicopathologic markers in HNSCC.
| Author | Year | Site of Cancer | Number of Patients | Age of Patients (years) | CAF marker used | Prior Therapy Received | Determination of CAF burden in samples |
|---|---|---|---|---|---|---|---|
| Akrish et al. ( | 2017 | Oral SCC | 65 | 28 patients <65, 37 patients >65 | α-SMA | No neoadjuvant therapy | • Method proposed by Bello et al. |
| Ding et al. ( | 2014 | Oral SCC | 50 | Mean: 53.5 (26–74) | α-SMA | No neoadjuvant therapy | • Based on CAF density |
| Fujii et al. ( | 2012 | Oral SCC | 108 | Mean: 66.4 (23–93) | α-SMA | No neoadjuvant therapy | • Modified classification system as described by Kellermann |
| Kellermann et al. ( | 2007 | Oral SCC | 83 | 42 patients ≤58, 41 patients >58 | α-SMA | No neoadjuvant therapy | • Rated as negative, scanty, or abundant as determined by three independent pathologists |
| Kellermann et al. ( | 2008 | Oral SCC | 38 | Mean: 61.1 (43–89) | α-SMA | No neoadjuvant therapy | • Rated as negative, scanty, or abundant as determined by three independent pathologists |
| Liang et al. ( | 2018 | Advanced Oral SCC | 26 | 12 patients <50, 14 patients ≥50 | α-SMA | Before chemotherapy sample used for meta-analysis | • Based on staining intensity multiplied by percentage of positive staining, Median cutoff between high and low |
| Lin et al. ( | 2017 | Oral SCC | 86 | 26 patients ≤50, 60 patients >50 | α-SMA | No neoadjuvant therapy | • Based on staining intensity multiplied by percentage of positive cells (each graded 0–3) |
| Luksic et al. ( | 2015 | Oral SCC | 152 | 26 patients ≤50, 60 patients >50 | α-SMA | No neoadjuvant therapy | • Based on Proportion of positive-staining area |
| Ramos-Vega et al. ( | 2020 | Head and Neck SCC | 29 | Mean: 57 (34–81) | α-SMA | No neoadjuvant therapy | • As described by Fujii et al. |
| Sun et al. ( | 2019 | Oral SCC | 47 | 17 patients <60, 30 patients ≥60 | α-SMA | No neoadjuvant therapy | • Method described in Cheng et al. ( |
| Takahashi et al. ( | 2016 | Oral SCC | 73 | 17 patients <60, 30 patients ≥60 | α-SMA | No neoadjuvant therapy | • According to previously described techniques (Kellermann et al., Fujii et al.) |
| Wang et al. ( | 2019 | Oral SCC | 121 | Mean: 60.2 (34–88) | α-SMA | No neoadjuvant therapy | • Method described by Fujii et al. |
| Zhang et al. ( | 2016 | Oral SCC | 48 | Not reported | α-SMA | No neoadjuvant therapy | • Based on extent of positive staining (high ≥25%) |
CAFs, Cancer-Associated Fibroblasts; SCC, Squamous Cell Carcinoma; α-SMA, alpha-Smooth Muscle Actin.
Figure 2Increased density of CAFs in HNSCC is associated with advanced T stage.
Figure 3Increased CAF density is associated with lymph node metastasis.
Figure 4Increased CAF density is associated with high clinical stage.
Figure 5Increased CAF density is associated with high rates of vascular invasion.
Figure 6Increased CAF density is associated with high rates of perineural invasion.
Figure 7Increased CAF density is associated with increased cellular proliferation, as determined by Ki67 staining.
Figure 8Increased CAF density is associated with poor differentiation of tumor.
Figure 9Increased CAF density is associated with local recurrence.
Figure 10Summary.